Brigitt E. Abbuehl

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

Barbara A. Konkle, Oleksandra Stasyshyn, Pratima Chowdary et al. · Blood · 2015 · 250 citations · Full text

Extended half‐life pegylated, full‐length recombinant factor <scp>VIII</scp> for prophylaxis in children with severe haemophilia A

Eric S. Mullins, Oleksandra Stasyshyn, María Román et al. · Haemophilia · 2016 · 79 citations · Full text

Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A

G. Auerswald, Alexis A. Thompson, Michael Recht et al. · Thrombosis and Haemostasis · 2012 · 49 citations · Full text

Immunohematology, Thrombosis, Transfusion Medicine +15

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level &lt;1%) or moderately severe (FIX level ≤2%) haemophilia B

Jerzy Windyga, Toshko Lissitchkov, Oleksandra Stasyshyn et al. · Haemophilia · 2013 · 48 citations

Efficacy and safety of pegylated full‐length recombinant factor <scp>VIII</scp> with extended half‐life for perioperative haemostasis in haemophilia A patients

B. Brand, Ralph A. Gruppo, Tung Wynn et al. · Haemophilia · 2016 · 28 citations · Full text